{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T05:20:28Z","timestamp":1712294428415},"reference-count":18,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.3892\/mco.2015.603","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T11:09:44Z","timestamp":1437044984000},"page":"1099-1102","source":"Crossref","is-referenced-by-count":4,"title":["A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma"],"prefix":"10.3892","volume":"3","author":[{"given":"HUSSEIN","family":"KHALED","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HAMDY ABDEL","family":"AZIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EMAD","family":"BARSOUM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GEORGE","family":"CHAHINE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ALI","family":"SHAMSEDDINE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GAMAL ABDEL","family":"METAAL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ABBAS","family":"OMAR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ABDUL RAHMAN","family":"JAZEIH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RASHA","family":"HAGGAG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ATEF","family":"BADRAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,7,16]]},"reference":[{"key":"key20180107145153_b1-mco-0-0-603","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00041552-200201000-00006","article-title":"Renal cancer: Molecular mechanisms and newer therapeutic options","volume":"11","author":"Karumanchi","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"key20180107145153_b2-mco-0-0-603","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"key20180107145153_b3-mco-0-0-603","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.juro.2010.09.012","article-title":"The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy","volume":"185","author":"Choueiri","year":"2011","journal-title":"J Urol"},{"key":"key20180107145153_b4-mco-0-0-603","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6602584","article-title":"Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on\/7 days off in patients with advanced, refractory solid tumours","volume":"92","author":"Awada","year":"2005","journal-title":"Br J Cancer"},{"key":"key20180107145153_b5-mco-0-0-603","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1158\/1078-0432.CCR-04-2658","article-title":"Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors","volume":"11","author":"Clark","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180107145153_b6-mco-0-0-603","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/annonc\/mdi310","article-title":"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on\/7 days off in patients with advanced, refractory solid tumors","volume":"16","author":"Moore","year":"2005","journal-title":"Ann Onco"},{"key":"key20180107145153_b7-mco-0-0-603","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107145153_b8-mco-0-0-603","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"key20180107145153_b9-mco-0-0-603","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl 18","key":"key20180107145153_b10-mco-0-0-603","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/jco.2006.24.18_suppl.4524","article-title":"The Sorafenib TARGETs Clinical Trial Group: Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. 2006 ASCO Annual Meeting Proceedings","volume":"24","author":"Eisen","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 18","key":"key20180107145153_b11-mco-0-0-603","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/jco.2007.25.18_suppl.5023","article-title":"Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. ASCO Annual Meeting Proceedings (Post-Meeting Edition)","volume":"25","author":"Bukowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180107145153_b12-mco-0-0-603","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1200\/JCO.2009.22.6480","article-title":"Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer","volume":"27","author":"Di Lorenzo","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107145153_b13-mco-0-0-603","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1002\/cncr.25327","article-title":"Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab","volume":"116","author":"Garcia","year":"2010","journal-title":"Cancer"},{"key":"key20180107145153_b14-mco-0-0-603","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107145153_b15-mco-0-0-603","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"key20180107145153_b16-mco-0-0-603","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000346484","article-title":"Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma","volume":"58","author":"Park","year":"2012","journal-title":"Chemotherapy"},{"key":"key20180107145153_b17-mco-0-0-603","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2217\/fon.14.48","article-title":"Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting","volume":"10","author":"Procopio","year":"2014","journal-title":"Future Oncol"},{"key":"key20180107145153_b18-mco-0-0-603","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ejca.2013.02.032","article-title":"Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort","volume":"49","author":"Iacovelli","year":"2013","journal-title":"Eur J Cancer"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mco.2015.603\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T03:04:44Z","timestamp":1599275084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mco.2015.603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,16]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,7,16]]},"published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.3892\/mco.2015.603"],"URL":"https:\/\/doi.org\/10.3892\/mco.2015.603","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,16]]}}}